semaglutide (Wegovy)

following a full submission:

semaglutide (Wegovy®) is accepted for restricted use within NHSScotland.

Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥30kg/m2 (obesity), or
• ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

SMC restriction: BMI of ≥30kg/m2* in the presence of at least one weight-related comorbidity. Patients should be treated in a specialist weight management service.
*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.

In a phase III study, semaglutide, as an adjunct to diet and exercise, was associated with significant reduction in body weight compared with placebo in patients with a BMI ≥30kg/m² or ≥ 27kg/m² if they had at least one weight-related comorbidity.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.